Determinants of surgical resection for pancreatic neuroendocrine tumors

被引:28
|
作者
Doi, Ryuichiro [1 ]
机构
[1] Otsu Red Cross Hosp, Dept Surg, Otsu, Shiga 5208511, Japan
关键词
Distal pancreatectomy; Gastrinoma; Insulinoma; Non-functioning tumor; Pancreaticoduodenectomy; ZOLLINGER-ELLISON-SYNDROME; ENDOCRINE NEOPLASIA TYPE-1; LIVER METASTASES; HEPATIC METASTASES; NATURAL-HISTORY; MANAGEMENT; SURGERY; LOCALIZATION; INSULINOMAS; GASTRINOMA;
D O I
10.1002/jhbp.224
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Pancreatic neuroendocrine tumors (pNETs) include functioning and non-functional tumors. Functioning tumors consist of tumors that produce a variety of hormones and their clinical effects. Therefore, determinants of resection of pNETs should be discussed for each group of tumors. Less than 10% of insulinomas are malignant, therefore more than 90% of the cases can be cured by surgical resection. Lymphadenectomy is generally not necessary in insulinoma operation. If preoperative localization of the insulinoma is completed, enucleation from the pancreatic body or tail, and distal pancreatectomy can be performed safely by laparoscopy. When preoperative localization of a sporadic insulinoma is not confirmed, surgical exploration is needed. Intraoperative localization of a tumor, intraoperative insulin sampling and frozen section are required. The crucial purpose of surgical resection is to control inappropriate insulin secretion by removing all insulinomas. Gastrinomas are usually located in the duodenum or pancreas, which secrete gastrin and cause Zollinger-Ellison syndrome (ZES). Duodenal gastrinomas are usually small, therefore they are not seen on preoperative imaging studies or endoscopic ultrasound, and can be found only at surgery if a duodenotomy is performed. In addition, lymph node metastasis is found in 40-60% of cases. Therefore, the experienced surgeons should direct operation for gastrinomas. Surgical exploration with duodenotomy should be performed at a laparotomy. Other functioning pNETs can occur in the pancreas or in other locations. Curative resection is always recommended whenever possible after optimal symptomatic control of the clinical syndrome by medical treatment. Indications for surgery depend on clinical symptom control, tumor size, location, extent, malignancy and presence of metastasis. A lot of non-functioning pNETs are found incidentally according to the quality improvement of imaging techniques. Localized, small, malignant non-functioning pNETs should be operated on aggressively, while in possibly benign tumors smaller than 2 cm the surgical risk-benefit ratio should be carefully weighted. Surgical liver resection is generally proposed in curative intent to all patients with operable metastases from G1 or G2 pNET. The benefits of surgical resection of liver metastases have been demonstrated in terms of overall survival and quality of life. Complete resection is associated with better long-term survival.
引用
收藏
页码:610 / 617
页数:8
相关论文
共 50 条
  • [1] PANCREATIC NEUROENDOCRINE TUMORS: SURGICAL RESECTION
    Belotto, Marcos
    Santos Crouzillard, Bruna do Nascimento
    Araujo, Karla de Oliveira
    Peixoto, Renata D'Alpino
    [J]. ABCD-ARQUIVOS BRASILEIROS DE CIRURGIA DIGESTIVA-BRAZILIAN ARCHIVES OF DIGESTIVE SURGERY, 2019, 32 (01):
  • [2] Surgical Indications and Outcomes of Resection for Pancreatic Neuroendocrine Tumors with Vascular Involvement
    Li, Amy Y.
    Visser, Brendan C.
    Dua, Monica M.
    [J]. CANCERS, 2022, 14 (09)
  • [3] Surgical Resection of Neuroendocrine Pancreatic Tumors - Even Upon the Presentation of Metastases
    Angst, E.
    Seiler, C. A.
    Gloor, B.
    [J]. AUSTRIAN JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, 2010, 3 (03): : 7 - 10
  • [4] Small pancreatic neuroendocrine tumors: observing and monitoring or prompt surgical resection
    Cienfuegos, Javier A.
    Hurtado-Pardo, Luis
    Rotellar, Fernando
    [J]. REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2022, 114 (01) : 1 - 4
  • [5] Indications for Surgical Resection in Low-Grade Pancreatic Neuroendocrine Tumors
    Fitzgerald, Timothy L.
    Mosquera, Catalina
    Vora, Haily S.
    Vohra, Nasreen A.
    Zervos, Emmanuel E.
    [J]. AMERICAN SURGEON, 2016, 82 (08) : 737 - 742
  • [6] Laparoscopic resection of pancreatic neuroendocrine tumors
    Abbas Al-Kurd
    Katya Chapchay
    Simona Grozinsky-Glasberg
    Haggi Mazeh
    [J]. World Journal of Gastroenterology, 2014, (17) : 4908 - 4916
  • [7] Laparoscopic resection of pancreatic neuroendocrine tumors
    Al-Kurd, Abbas
    Chapchay, Katya
    Grozinsky-Glasberg, Simona
    Mazeh, Haggi
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (17) : 4908 - 4916
  • [8] Prognostic Factors for Recurrence of Sporadic Pancreatic Neuroendocrine Tumors after Surgical Resection
    Figueira, E. R. R.
    Bacchella, T.
    Jureidini, R.
    Cunha, J. E. M.
    Namur, G. N.
    Ribeiro, T. C.
    Okubo, J.
    Fernandes, A. G., V
    Cecconello, I
    [J]. NEUROENDOCRINOLOGY, 2016, 103 : 97 - 97
  • [9] The current role of surgical resection and cytoreduction in the treatment of pancreatic neuroendocrine (NE) tumors
    Bloomston, Mark
    Al-Saif, Osama
    Muscarella, Peter
    Melvin, W. Scott
    Martin, Edward W.
    Shah, Manisha
    Frankel, Wendy L.
    Ellison, E. Christopher
    [J]. GASTROENTEROLOGY, 2006, 130 (04) : A881 - A881
  • [10] Evaluation of Survival Following Surgical Resection for Small Nonfunctional Pancreatic Neuroendocrine Tumors
    Sugawara, Toshitaka
    Rodriguez Franco, Salvador
    Kirsch, Michael J.
    Colborn, Kathryn L.
    Ishida, Jun
    Grandi, Samuele
    Al-Musawi, Mohammed H.
    Gleisner, Ana
    Del Chiaro, Marco
    Schulick, Richard D.
    [J]. JAMA NETWORK OPEN, 2023, 6 (03)